H2020Индивидуална стипендия2016–2018

THERAGEL · Development of a chemotherapeutic gel for glioblastoma multiforme treatment

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2016-04-01 → 2018-03-31
Финансиране от ЕС: 175 866 €
Участници: 2
Схема: MSCA-IF-EF-ST

Линиите свързват координатора с партньорите.

Накратко на български

Разработва се специален инжектируем гел за локално подаване на химиотерапия директно в зоната на глиобластом (агресивен рак на мозъка). Това е важно, за да се повиши ефективността на лечението и да се намалят страничните ефекти от системното приложение на лекарствата.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Development of a chemotherapeutic gel for glioblastoma multiforme treatment

The Theragel project was designed to create a novel therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive and common form of brain cancer. GBM typically results in death in the first 15 months after diagnosis. It accounts for 15.4% of all primary brain tumours and its relative survival estimates are quite low; 5% of patients survive five years post diagnosis. The average incidence of GBM in Europe is approximately 3.2 per 100,000 individuals. Moreover, an increase is projected for the number of patients newly diagnosed with GBM (35,420 new cases are predicted in 2033). For the better chances of survival and the wellbeing of the patients, there is a great need for new strategies to obtain more efficient treatments. Nowadays, the current standard of care for GBM comprises surgical resection followed by a combination of implantation of carmustine wafers (Gliadel®) and concomitant temozolomide (TMZ) administered systemically. This administration process increases the likelihood of unwanted side effects and sometimes it is not effective due to the restrictive nature of the blood brain barrier. In addition, the cytotoxic effects of carmustine are hindered by poor surface contact with the tumour, large diffusion distances through brain tissues and increased risk of side-effects. Therefore, the state-of-the-art is far from optimal and new strategies are warranted to deliver therapies with higher efficacy and low toxicity. Due to the treatment limitations, the main objective of the Theragel project was the development of a safe, innovative and effective delivery system for the local administration of chemotherapeutic drugs into a specific area of the brain. In particular, I have designed a novel delivery system combining an injectable polymer matrix containing the antitumoral drug TMZ, and gated mesoporous silica nanoparticles (MSNs) loaded with another chemotherapeutic compound. The polymer matrix was designed to provide a sustained release of TMZ and MSNs, with the intention to selectively deliver the cargo in GBM cells.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Advanced nanotechnology-based materials offer new solutions to the challenges associated with the non-specific delivery of therapeutics that leads to ineffective treatments, especially in oncology. Currently, both therapeutic and diagnostic molecules are administered systemically, increasing the likelihood of unwanted side effects. THERAGEL will develop a novel delivery system that enables selective, targeted local delivery of therapeutics and imaging agents. Specifically, I will use this delivery system to design a therapy for the treatment of glioblastoma multiforme, the most aggressive form of brain cancer. THERAGEL will comprise a unique combination of advanced injectable polymeric depots and targeted nanoparticles with both chemotherapeutic and imaging agent payloads (‘theranostic’ nanoparticle). The polymeric depots will provide a continuous release of free chemotherapeutic drug, with a tunable profile depending on the polymer composition, and cancer-targeted nanoparticles that will release the theranostic cargo only after selective uptake by cancer cells. THERAGEL will advance the state of the art in nanomedicines through advances to the individual components of the developed delivery system. This proposal represents a unique opportunity in the context of nanotheranostics for tailored chemotherapy, and means a significant step towards its clinical translation. The technologies developed will address three out of the six Horizon 2020 Key Enabling Technologies themes, which are a key part of the programme funding strategy: Nanotechnology, Advanced Biomaterials and Advanced Manufacturing technologies. This research constitutes a highly multidisciplinary approach with large impact in near future advanced therapies and with a great chance for collaboration and networking between European research groups and industrial partners. Combining my expertise in gated-materials with the host PI’s delivery systems development experience will make this new direction possible

Оригинален текст от CORDIS (на английски).

Участници

THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN · DublinКоординаторИрландия
ROYAL COLLEGE OF SURGEONS IN IRELAND · DUBLIN 2Ирландия